{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:54:01Z","timestamp":1791143641520,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1007\/s11910-007-0031-5","type":"journal-article","created":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T05:41:27Z","timestamp":1178602887000},"page":"200-207","source":"Crossref","is-referenced-by-count":22,"title":["Update on the management of familial central nervous system tumor syndromes"],"prefix":"10.1007","volume":"7","author":[{"given":"Andreas F.","family":"Hottinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Khakoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,5,9]]},"reference":[{"key":"31_CR1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/hmg\/10.7.747","volume":"10","author":"D.H. Gutmann","year":"2001","unstructured":"Gutmann DH: The neurofibromatoses: when less is more. Hum Mol Genet 2001, 10:747\u2013755.","journal-title":"Hum Mol Genet"},{"key":"31_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","volume":"89","author":"J.M. Friedman","year":"1999","unstructured":"Friedman JM: Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999, 89:1\u20136.","journal-title":"Am J Med Genet"},{"key":"31_CR3","doi-asserted-by":"crossref","unstructured":"Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988, 45:575\u2013578.","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"31_CR4","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1212\/01.wnl.0000203645.25173.70","volume":"66","author":"M. Quigg","year":"2006","unstructured":"Quigg M, Rust RS, Miller JQ: Clinical findings of the phakomatoses: neurofibromatosis. Neurology 2006, 66:E23\u201324.","journal-title":"Neurology"},{"key":"31_CR5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0022-3476(05)83163-4","volume":"124","author":"K.J. Hofman","year":"1994","unstructured":"Hofman KJ, Harris EL, Bryan RN, Denckla MB: Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 1994, 124:S1\u20138.","journal-title":"J Pediatr"},{"key":"31_CR6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1212\/01.WNL.0000150544.00016.69","volume":"64","author":"T.L. Rosser","year":"2005","unstructured":"Rosser TL, Vezina G, Packer RJ: Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 2005, 64:553\u2013555.","journal-title":"Neurology"},{"key":"31_CR7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/micr.20188","volume":"26","author":"A. Rawal","year":"2006","unstructured":"Rawal A, Yin Q, Roebuck M, et al.: Atypical and malignant peripheral nerve-sheath tumors of the brachial plexus: report of three cases and review of the literature. Microsurgery 2006, 26:80\u201386.","journal-title":"Microsurgery"},{"key":"31_CR8","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1056\/NEJMc066006","volume":"354","author":"B. Bausch","year":"2006","unstructured":"Bausch B, Borozdin W, Neumann HP: Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med 2006, 354:2729\u20132731.","journal-title":"N Engl J Med"},{"key":"31_CR9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/pbc.20655","volume":"46","author":"C.D. Jahraus","year":"2006","unstructured":"Jahraus CD, Tarbell NJ: Optic pathway gliomas. Pediatr Blood Cancer 2006, 46:586\u2013596.","journal-title":"Pediatr Blood Cancer"},{"key":"31_CR10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000083744","volume":"40","author":"T. Ogura","year":"2004","unstructured":"Ogura, T, Adachi J, Nishikawa R, et al.: Synchronous optic and pineal pilocytic astrocytomas in a paediatric patient with neurofibromatosis type 1. Pediatr Neurosurg 2004, 40:301\u2013305.","journal-title":"Pediatr Neurosurg"},{"key":"31_CR11","first-page":"1114","volume":"38","author":"A.V. Deliganis","year":"1996","unstructured":"Deliganis AV, Geyer JR, Berger MS: Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma. Neurosurgery 1996, 38:1114\u20131148; discussion 1118\u20131119.","journal-title":"Neurosurgery"},{"key":"31_CR12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajmg.a.20211","volume":"122","author":"A. King","year":"2003","unstructured":"King A, Listernick R, Charrow J, et al.: Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet 2003, 122:95\u201399.","journal-title":"Am J Med Genet"},{"key":"31_CR13","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ejca.2006.02.022","volume":"42","author":"E. Opocher","year":"2006","unstructured":"Opocher E, Kremer LC, Da Dalt L, et al.: Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer 2006, 42:1807\u20131816.","journal-title":"Eur J Cancer"},{"key":"31_CR14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ana.410410204","volume":"41","author":"R. Listernick","year":"1997","unstructured":"Listernick R, Louis DN, Packer RJ, Gutmann DH: Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997, 41:143\u2013149.","journal-title":"Ann Neurol"},{"key":"31_CR15","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/01.WNL.0000144341.16830.01","volume":"63","author":"R. Listernick","year":"2004","unstructured":"Listernick R, Ferner RE, Piersall L, et al.: Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 2004, 63:1944\u20131946.","journal-title":"Neurology"},{"key":"31_CR16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/02688690310001601216","volume":"17","author":"J. Astrup","year":"2003","unstructured":"Astrup J: Natural history and clinical management of optic pathway glioma. Br J Neurosurg 2003, 17:327\u2013335.","journal-title":"Br J Neurosurg"},{"key":"31_CR17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00019052-200312000-00003","volume":"16","author":"D. Walker","year":"2003","unstructured":"Walker D: Recent advances in optic nerve glioma with a focus on the young patient. Curr Opin Neurol 2003, 16:657\u2013664.","journal-title":"Curr Opin Neurol"},{"key":"31_CR18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2005.03.8638","volume":"24","author":"B.C. Widemann","year":"2006","unstructured":"Widemann BC, Salzer WL, Arceci RJ, et al.: Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006, 24:507\u2013516.","journal-title":"J Clin Oncol"},{"key":"31_CR19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/088307389901400602","volume":"14","author":"G. Perilongo","year":"1999","unstructured":"Perilongo G, Moras P, Carollo C, et al.: Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility. J Child Neurol 1999, 14:352\u2013356.","journal-title":"J Child Neurol"},{"key":"31_CR20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00006123-199702000-00018","volume":"40","author":"A. Broniscer","year":"1997","unstructured":"Broniscer A, Gajjar A, Bhargava R, et al.: Brain stem involvement in children with neurofibromatosis type 1: role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma. Neurosurgery 1997, 40:331\u2013337; discussion 337\u2013338.","journal-title":"Neurosurgery"},{"key":"31_CR21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3171\/jns.1997.86.5.0747","volume":"86","author":"R.J. Packer","year":"1997","unstructured":"Packer RJ, Ater J, Allen J, et al.: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997, 86:747\u2013754.","journal-title":"J Neurosurg"},{"key":"31_CR22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1531-8249(199903)45:3<393::AID-ANA17>3.0.CO;2-B","volume":"45","author":"J. Grill","year":"1999","unstructured":"Grill J, Couanet D, Cappelli C, et al.: Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 1999, 45:393\u2013396.","journal-title":"Ann Neurol"},{"key":"31_CR23","doi-asserted-by":"crossref","unstructured":"Hamaratoglu F, Willecke M, Kango-Singh M, et al.: The tumour-suppressor genes NF2\/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2005, 27\u201336.","DOI":"10.1038\/ncb1339"},{"key":"31_CR24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00130404-200401000-00006","volume":"10","author":"Y. Hirokawa","year":"2004","unstructured":"Hirokawa, Y, Tikoo A, Huynh J, et al.: A clue to the therapy of neurofibromatosis type 2: NF2\/merlin is a PAK1 inhibitor. Cancer J 2004, 10:20\u201326.","journal-title":"Cancer J"},{"key":"31_CR25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/342716","volume":"71","author":"M.E. Baser","year":"2002","unstructured":"Baser ME, Friedman JM, Aeschliman D, et al.: Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002, 71:715\u2013723.","journal-title":"Am J Hum Genet"},{"key":"31_CR26","first-page":"603","volume":"84","author":"D.G. Evans","year":"1992","unstructured":"Evans DG, Huson SM, Donnai D, et al.: A clinical study of type 2 neurofibromatosis. Q J Med 1992, 84:603\u2013618.","journal-title":"Q J Med"},{"key":"31_CR27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajmg.1320520411","volume":"52","author":"D.M. Parry","year":"1994","unstructured":"Parry DM, Eldridge R, Kaiser-Kupfer MI, et al.: Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994, 52:450\u2013461.","journal-title":"Am J Med Genet"},{"key":"31_CR28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/02688690500081206","volume":"19","author":"D.G. Evans","year":"2005","unstructured":"Evans DG, Baser ME, O\u2019Reilly B, et al.: Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005, 19:5\u201312.","journal-title":"Br J Neurosurg"},{"key":"31_CR29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3171\/jns.2001.94.2.0217","volume":"94","author":"J.W. Brennan","year":"2001","unstructured":"Brennan JW, Rowed DW, Nedzelski JM, Chen JM: Cerebrospinal fluid leak after acoustic neuroma surgery: influence of tumor size and surgical approach on incidence and response to treatment. J Neurosurg 2001, 94:217\u2013223.","journal-title":"J Neurosurg"},{"key":"31_CR30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jmg.2005.036319","volume":"43","author":"D.G. Evans","year":"2006","unstructured":"Evans DG, Birch JM, Ramsden RT, et al.: Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006, 43:289\u2013294.","journal-title":"J Med Genet"},{"key":"31_CR31","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/014556130208101210","volume":"81","author":"S.Y. Ho","year":"2002","unstructured":"Ho SY, Kveton JF: Rapid growth of acoustic neuromas after stereotactic radiotherapy in type 2 neurofibromatosis. Ear Nose Throat J 2002, 81:831\u2013833.","journal-title":"Ear Nose Throat J"},{"key":"31_CR32","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/01.mao.0000232010.01116.e9","volume":"27","author":"T. Lenarz","year":"2006","unstructured":"Lenarz T, Lim HH, Reuter G, et al.: The auditory midbrain implant: a new auditory prosthesis for neural deafnessconcept and device description. Otol Neurotol 2006, 27:838\u2013843.","journal-title":"Otol Neurotol"},{"key":"31_CR33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00593938","volume":"32","author":"L. Mayfrank","year":"1990","unstructured":"Mayfrank L, Mohadjer M, Wullich B.: Intracranial calcified deposits in neurofibromatosis type 2. A CT study of 11 cases. Neuroradiology 1990, 32:33\u201337.","journal-title":"Neuroradiology"},{"key":"31_CR34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"P.B. Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med 2006, 355:1345\u20131356.","journal-title":"N Engl J Med"},{"key":"31_CR35","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","volume":"13","author":"E.S. Roach","year":"1998","unstructured":"Roach ES, Gomez MR, Northrup H: Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998, 13:624\u2013628.","journal-title":"J Child Neurol"},{"key":"31_CR36","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/08830738040190090801","volume":"19","author":"E.A. Thiele","year":"2004","unstructured":"Thiele EA: Managing epilepsy in tuberous sclerosis complex. J Child Neurol 2004, 19:680\u2013686.","journal-title":"J Child Neurol"},{"key":"31_CR37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/08830738050200040901","volume":"20","author":"P. Curatolo","year":"2005","unstructured":"Curatolo P, Bombardieri R, Verdecchia M, Seri S: Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment. J Child Neurol 2005, 20:318\u2013325.","journal-title":"J Child Neurol"},{"key":"31_CR38","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1212\/01.WNL.0000142039.14522.1A","volume":"63","author":"S. Goh","year":"2004","unstructured":"Goh S, Butler W, Thiele EA: Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 2004, 63:1457\u20131461.","journal-title":"Neurology"},{"key":"31_CR39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000120311","volume":"13","author":"L.N. Sutton","year":"1987","unstructured":"Sutton LN: Current management of low-grade astrocytomas of childhood. Pediatr Neurosci 1987, 13:98\u2013107.","journal-title":"Pediatr Neurosci"},{"key":"31_CR40","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"D.N. Franz","year":"2006","unstructured":"Franz DN, Leonard J, Tudor C, et al.: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006, 59:490\u2013498.","journal-title":"Ann Neurol"},{"key":"31_CR41","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1067\/S0022-3476(03)00494-3","volume":"143","author":"R.S. Bader","year":"2003","unstructured":"Bader RS, Chitayat D, Kelly E, et al.: Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex. J Pediatr 2003, 143:620\u2013624.","journal-title":"J Pediatr"},{"key":"31_CR42","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/332268a0","volume":"332","author":"B.R. Seizinger","year":"1988","unstructured":"Seizinger BR, Rouleau GA, Ozelius LJ, et al.: Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988, 332:268\u2013269.","journal-title":"Nature"},{"key":"31_CR43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jjco\/hyl052","volume":"36","author":"T. Shuin","year":"2006","unstructured":"Shuin T, Yamasaki I, Tamura K, et al.: Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol 2006, 36:337\u2013343.","journal-title":"Jpn J Clin Oncol"},{"key":"31_CR44","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/jama.1995.03520310062031","volume":"273","author":"W.M. Linehan","year":"1995","unstructured":"Linehan WM, Lerman MI, Zbar B: Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995, 273:564\u2013570.","journal-title":"JAMA"},{"key":"31_CR45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10689-004-5347-6","volume":"4","author":"S. Glasker","year":"2005","unstructured":"Glasker S: Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features. Fam Cancer 2005, 4:37\u201342.","journal-title":"Fam Cancer"},{"key":"31_CR46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2796.1998.00337.x","volume":"243","author":"S. Richard","year":"1998","unstructured":"Richard S, Campello C, Taillandier L, et al.: Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group. J Intern Med 1998, 243:547\u2013553.","journal-title":"J Intern Med"},{"key":"31_CR47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3171\/jns.2003.98.1.0082","volume":"98","author":"J.E. Wanebo","year":"2003","unstructured":"Wanebo JE, Lonser RR, Glenn GM, Oldfield EH: The natural history of hemangioblastom as of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 2003, 98:82\u201394.","journal-title":"J Neurosurg"},{"key":"31_CR48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4103\/0028-3886.27152","volume":"54","author":"S. Dwarakanath","year":"2006","unstructured":"Dwarakanath S, Suri A, Sharma BS, Mehta VS: Intracranial hemangioblastomas: an institutional experience. Neurol India 2006, 54:276\u2013278.","journal-title":"Neurol India"},{"key":"31_CR49","first-page":"55","volume":"48","author":"J.E. Conway","year":"2001","unstructured":"Conway JE, Chou D, Clatterbuck RE, et al.: Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease. Neurosurgery 2001, 48:55\u201362.","journal-title":"Neurosurgery"},{"key":"31_CR50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3171\/jns.2003.98.1.0095","volume":"98","author":"R.J. Weil","year":"2003","unstructured":"Weil RJ, Lonser RR, DeVroom HL, et al.: Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003, 98:95\u2013105.","journal-title":"J Neurosurg"},{"key":"31_CR51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B. Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125\u2013134.","journal-title":"N Engl J Med"},{"key":"31_CR52","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2006.08.5415","volume":"24","author":"R.J. Motzer","year":"2006","unstructured":"Motzer RJ, Bukowski RM: Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006, 24:5601\u20135608.","journal-title":"J Clin Oncol"},{"key":"31_CR53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0039-6257(01)00245-4","volume":"46","author":"A.D. Singh","year":"2001","unstructured":"Singh AD, Shields CL, Shields JA: von Hippel-Lindau disease. Surv Ophthalmol 2001, 46:117\u2013142.","journal-title":"Surv Ophthalmol"},{"key":"31_CR54","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/jama.1997.03540420057030","volume":"277","author":"T.J. Manski","year":"1997","unstructured":"Manski TJ, Heffner DK, Glenn GM, et al.: Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 1997, 277:1461\u20131466.","journal-title":"JAMA"},{"key":"31_CR55","first-page":"1","volume":"150","author":"P. Kleihues","year":"1997","unstructured":"Kleihues, P, Schauble B, Zur Hausen A, et al.: Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997, 150:1\u201313.","journal-title":"Am J Pathol"},{"key":"31_CR56","first-page":"6643","volume":"63","author":"M. Olivier","year":"2003","unstructured":"Olivier M, Goldgar De, Sodha N, et al.: Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003, 63:6643\u20136650.","journal-title":"Cancer Res"},{"key":"31_CR57","first-page":"581","volume":"88","author":"T. Frebourg","year":"2001","unstructured":"Frebourg T, Abel A, Bonaiti-Pellie C, et al.: Li-Fraumeni syndrome: update, new data and guidelines for clinical management. Bull Cancer 2001, 88:581\u2013587.","journal-title":"Bull Cancer"},{"key":"31_CR58","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/00006123-200010000-00020","volume":"47","author":"M.D. Taylor","year":"2000","unstructured":"Taylor MD, Mainprize TG, Rutka JT: Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 2000, 47:888\u2013901.","journal-title":"Neurosurgery"},{"key":"31_CR59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00005792-198703000-00002","volume":"66","author":"R.J. Gorlin","year":"1987","unstructured":"Gorlin RJ: Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987, 66:98\u2013113.","journal-title":"Medicine (Baltimore)"},{"key":"31_CR60","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2662::AID-CNCR24>3.0.CO;2-0","volume":"85","author":"A.O. Vortmeyer","year":"1999","unstructured":"Vortmeyer AO, Stavrou T, Selby D, et al.: Deletion analysis of the adenomatous polyposis coli and PTCH gene loci in patients with sporadic and nevoid basal cell carcinoma syndrome-associated medulloblastoma. Cancer 1999, 85:2662\u20132667.","journal-title":"Cancer"},{"key":"31_CR61","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1593\/neo.03454","volume":"6","author":"C. Raffel","year":"2004","unstructured":"Raffel C: Medulloblastoma: molecular genetics and animal models. Neoplasia 2004, 6:310\u2013322.","journal-title":"Neoplasia"},{"key":"31_CR62","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00006123-199602000-00007","volume":"68","author":"A.L. Albright","year":"1996","unstructured":"Albright AL, Wisoff JH, Zeltzer PM, et al.: Effects of medulloblastoma resections on outcome in children: a report from the Children\u2019 Cancer Group. Neurosurgery 1996, 68:265\u2013271.","journal-title":"Neurosurgery"},{"key":"31_CR63","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3171\/jns.1989.70.4.0536","volume":"70","author":"J.L. Hubbard","year":"1989","unstructured":"Hubbard JL, Scheithauer BW, Kispert DB, et al.: Adult cerebellar medulloblastomas: the pathological, radiographic, and clinical disease spectrum. J Neurosurg 1989, 70:536\u2013544.","journal-title":"J Neurosurg"},{"key":"31_CR64","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3171\/jns.1994.81.5.0690","volume":"81","author":"R.J. Packer","year":"1994","unstructured":"Packer RJ, Sutton LN, Elterman R, et al.: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994, 81:690\u2013698.","journal-title":"J Neurosurg"},{"key":"31_CR65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1750-3639.1995.tb00588.x","volume":"5","author":"D.N. Louis","year":"1995","unstructured":"Louis DN, von Deimling A: Hereditary tumor syndromes of the nervous system: overview and rare syndromes. Brain Pathol 1995, 5:145\u2013151.","journal-title":"Brain Pathol"},{"key":"31_CR66","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJM199503303321302","volume":"332","author":"S.R. Hamilton","year":"1995","unstructured":"Hamilton SR, Liu B, Parsons RE, et al.: The molecular basis of Turcot\u2019 syndrome. N Engl J Med 1995, 332:839\u2013847.","journal-title":"N Engl J Med"},{"key":"31_CR67","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/1235","volume":"19","author":"A. Cristofano Di","year":"1998","unstructured":"Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: PTEN is essential for embryonic development and tumour suppression. Nat Genet 1998, 19:348\u2013355.","journal-title":"Nat Genet"},{"key":"31_CR68","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0959-4388(02)00354-9","volume":"12","author":"S. Backman","year":"2002","unstructured":"Backman S, Stambolic V, Mak T: PTEN function in mammalian cell size regulation. Curr Opin Neurobiol 2002, 12:516\u2013522.","journal-title":"Curr Opin Neurobiol"},{"key":"31_CR69","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2005.11.042","volume":"241","author":"L.M. Chow","year":"2006","unstructured":"Chow LM, Baker SJ: PTEN function in normal and neoplastic growth. Cancer Lett 2006, 241:184\u2013196.","journal-title":"Cancer Lett"},{"key":"31_CR70","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1212\/WNL.43.7.1436","volume":"43","author":"C.J. Lyons","year":"1993","unstructured":"Lyons CJ, Wilson CB, Horton JC: Association between meningioma and Cowden\u2019 disease. Neurology 1993, 43:1436\u20131437.","journal-title":"Neurology"},{"key":"31_CR71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1017\/S031716710002151X","volume":"24","author":"S. Tuli","year":"1997","unstructured":"Tuli S, Provias JP, Bernstein M: Lhermitte-Duclos disease: literature review and novel treatment strategy. Can J Neurol Sci 1997, 24:155\u2013160.","journal-title":"Can J Neurol Sci"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-007-0031-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-007-0031-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-007-0031-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T19:50:44Z","timestamp":1587498644000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-007-0031-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1007\/s11910-007-0031-5","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}